top of page
Search

Baxter Limits Orders for Select IV Medications While Lots Undergo Testing

3 days ago
2 min read

The drug name on the order may look exactly like it did yesterday. What arrives in the room can still change. When a familiar IV presentation is hard to get, pharmacy may need to source a different product or change how it’s prepared and delivered to the OR.

In its November 4 U.S. allocation notice, Baxter said environmental monitoring at its Round Lake drug delivery facility produced atypical results. The company is conducting additional testing on specific lots before releasing them. In the meantime, Baxter placed order limits on certain IV products from that facility.


What’s on allocation?

The notice covers selected presentations of nicardipine, clindamycin, daptomycin, human insulin, amiodarone, vancomycin and vasopressin. Allocations range from 25% to 75% depending on the specific product, and Baxter says quantities above a customer’s allocation will be canceled automatically. The company estimated overall supply recovery in eight to ten weeks from the notice, with different expected end dates for individual limits.

Those details matter when your team is trying to figure out what’s actually affected. For example, Baxter listed two vasopressin presentations with different allocation levels and expected end dates. Pharmacy and purchasing can use the product code or National Drug Code in the notice to match what they order to the applicable limit.


Cefazolin is a separate supply issue

In a separate November 4 update, the American Society of Health-System Pharmacists reported that Baxter had discontinued three cefazolin premixed bag presentations and expected remaining supplies to run out in early 2027. Other cefazolin presentations remained available. A discontinued premix and a temporary order limit call for different planning, even when both show up as a change to what pharmacy can send to the room.


Where the handoff matters

If pharmacy moves from a familiar premix to a different presentation, perioperative teams need to know how the product will arrive, who prepares it and whether anything changes about delivery to the room. When the medication is a pre-incision antibiotic, even a change in where it’s prepared can affect how far ahead the team needs to request it.

Who tells the OR when the usual IV product changes at your facility? That conversation is easier before the case than when the team is waiting to start.


Baxter International Inc. “U.S. Allocation Update – Pharma.” Medline, 4 Nov. 2026, https://www.medline.com/media/assets/pdf/vendor-list/Baxter_Non_Ceph_Allocation_4_November_2026.pdf.

Wheeler, Michelle. “Cefazolin Injection.” ASHP Drug Shortages, American Society of Health-System Pharmacists, updated 4 Nov. 2026, https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=432.

 
 
 

Recent Posts

See All

Comments


For the love of surgery surgical tech

Empowering surgical professionals through education, connection, and real-world experience.

  • Instagram
  • TikTok
  • YouTube
  • LinkedIn
  • Facebook

Join Our Newsletter

Stay inspired and up to date on new workshops and resources by becoming a member & joining our email list.

© 2026 For The Love of Surgery. All Rights Reserved.

For the Love of Surgery is a 501(c)(3) organization and

your donation is tax deductible within the guidelines of US law.

Tax ID: 41-3695452​

4651 Mallow St, Houston, TX 77051
| Privacy Policy | Terms of Use | Disclaimer |

bottom of page